ArticleHuman brain mapping2024
Evaluation of ComBat Harmonization for Reducing Across-Tracer Differences in Regional Amyloid PET Analyses.
Article in Human brain mapping, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- TRAECR: A Tool for Preprocessing Positron Emission Tomography Imaging for Statistical Modeling.ArXiv · 2026Article
- Prediction of alzheimer's disease time to dementia onset using cross-sectional data from spatiotemporal biomarker progression patterns.European journal of nuclear medicine and molecular imaging · 2026Article
- SPECT and PET imaging of Alzheimer's disease revisited: from biomarkers to artificial intelligence-based prediction.Annals of nuclear medicine · 2026Review
- AI-enabled multimodal neuroimaging for neurotransmitter mapping in normal aging and age-related disease.Frontiers in aging neuroscience · 2026Review
- Real-world application of lecanemab in early-stage alzheimer's disease: a single-center prospective cohort analysis.Alzheimer's research & therapy · 2025Article
- Analyzing heterogeneity in Alzheimer disease using multimodal normative modeling on imaging-based ATN biomarkers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
Differences in amyloid positron emission tomography (PET) radiotracer pharmacokinetics and binding properties lead to discrepancies in amyloid-β uptake estimates. Harmonization of tracer-specific biases is crucial for optimal performance of downstream tasks. Here, we investigated the efficacy of ComBat, a data-driven harmonization model, for reducing tracer-specific biases in regional amyloid PET measurements from [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.